News by region

Abivax starts testing ABX464 with older Covid-19 patients

Abivax has treated the first patient in its Phase 2b/3 study of ABX464 in COVID-19 patients at the University Hospital Center in Nice, France (CHU Nice) in a randomized, double-blind, placebo-controlled study, to see the the effects of early treatment in 1034 Covid-19 older or high-risk patients.

Posted in Europe, news | Tagged , , , | Leave a comment

EUSA Pharma gets FDA’s green light for further testing of siltuximab in COVID-19 patients with acute respiratory distress syndrome

EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, received the approval from the U.S. Food & Drug Administration (FDA) for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to test intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).

Posted in Europe, news | Tagged , , | Leave a comment

Gilead Sciences’ top person, Daniel O’Day on 5-day treatment course with remdesivir for $2,340 per patient

Remdevisir has become a popular word these days, along with Covid-19, Coronavirus, the city of Wuhan, and for a good reason. The headline in all the news, the pricing of remdevisir, has been flooding the internet, and pretty much the TV.

Posted in news, North America | Tagged , , , | Leave a comment

Bavarian Nordic Announces European Marketing Authorization for Ebola Vaccine

Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the European Commission has granted marketing authorization for MVABEA® (MVA-BN Filo) together with ZABDENO® (Ad26.ZEBOV), which collectively constitute Janssen’s Ebola vaccine regimen. The approval follows a Positive Opinion by the CHMP of the European Medicines Agency (EMA) in May 2020.

Posted in Europe, news | Tagged , , | Leave a comment

Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2

In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor

Posted in news, North America | Tagged , , , | Leave a comment

Health Canada lets certain COVID-19 patients to take NuvOx Pharma’s Oxygen therapeutic in phase II clinical trial (edit)

NuvOx Pharma ensured the continuation of Phase 2 clinical trial of its NanO2 in Covid-19 patients with acute hypoxic respiratory failure, as it got No Objection Letter from Health Canada.

Posted in news, North America | Tagged , , | Leave a comment

Sinovac ends Covid-19 affected first quarter 2020 with decerase in sales

Sinovac Biotech, a provider of biopharmaceutical producs in China, has reported sales for the first quarter of 2020 at $15.4 million, a decrease of 57.9% from $36.6 million in the prior year period, with a loss attributed to common shareholders of $7.4 million, in the same period.

Posted in Asia, news | Leave a comment

LEO Pharma strengthens global leadership team

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma, a global leader in medical dermatology, today announced that Dr. Monica Shaw, M.D., and Nathalie Joannes

Posted in Europe, news | Tagged | Leave a comment

Vertex expands deal with NHS England to Include Kaftrio Kalydeco combo

As Vertex expands deal with NHS England to include Kaftrio in combination with Kalydeco, the cysitc fibrosis patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the European Commission.

Posted in Europe, news | Tagged , , , , , , , | Leave a comment

Stevanato Group ends 2019 with double-digit growth and revenues of €570M

Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, continued its growth in 2019, recording a positive trend on key financial indicators, with consolidated revenues of €570.3 million, an increase of +10.9% compared to 2018.

Posted in Europe, news | Tagged | Leave a comment